(LEGN) Legend Biotech - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US52490G1022

CAR-T, Cell, Therapies, Oncology, Cancers

LEGN EPS (Earnings per Share)

EPS (Earnings per Share) of LEGN over the last years for every Quarter: "2020-03": -0.34, "2020-06": -2.5, "2020-09": -1.01, "2020-12": -0.87, "2021-03": -1.22, "2021-06": -1.32, "2021-09": -1.73, "2021-12": -1.21, "2022-03": -0.55, "2022-06": -2.5, "2022-09": -1.08, "2022-12": -1.71, "2023-03": -1.36, "2023-06": -2.27, "2023-09": -0.68, "2023-12": -1.59, "2024-03": -0.66, "2024-06": -0.2, "2024-09": -1.37, "2024-12": 0.29, "2025-03": -1.1,

LEGN Revenue

Revenue of LEGN over the last years for every Quarter: "2020-03": 11.546, "2020-06": 11.6, "2020-09": 11.747, "2020-12": 40.783, "2021-03": 13.682, "2021-06": 20.233, "2021-09": 16.882, "2021-12": 38.995, "2022-03": 40.827, "2022-06": 11.971, "2022-09": 27.361, "2022-12": 27.633, "2023-03": 36.336, "2023-06": 73.33, "2023-09": 96.013, "2023-12": 79.464, "2024-03": 93.991, "2024-06": 186.523, "2024-09": 160.205, "2024-12": 186.522, "2025-03": 195.053,

Description: LEGN Legend Biotech

Legend Biotech Corporation is a pioneering biopharmaceuticalaceutical company that focuses on developing and commercializing innovative cell therapies for cancer treatment. The operating through its subsidiaries, the company has a robust pipeline of novel therapies targeting various oncology indications, with a primary focus on multiple myeloma treatment using its flagship product, ciltacabel, a CAR-T therapy. Legend Biotech is also advancing its research in other areas, including including Non-Hodgans Lymphoma, leukemia, and solid tumors through its diverse portfolio of aut autologous and allogeneic CAR-T and CAR-N NK product candidates.P>

With a strong foundation in research and development, established through partnerships with major pharmaceutical companies like Janssen Biotech and Novartis,, the company is is poised for growth, driven by the potential of its lead product and the breadth of its pipeline. As a publicly traded company on NASDAQ under the ticker symbol LEGN, Legend, Legend Biotech has attracted significant investor interest, reflected in its market capitalization. The companys commitment commitment commitment to advancing cancer treatment through cutting-edge therapies positions it as a key player in the biotechnology sector.

From a technical analysis perspective, LEGNs stock price has shown volatility, with its 52-week range indicating a significant fluctuation between $27.73 and $59.59. The current price of $35.00 is near the middle of this range this range, and the Simple Moving Averages (SSMA20, SMA50, and SMA200)200) suggest a potential for potential for recovery, given that the short-term averages are converging. The Average True Range ( (ATR) of 1..72 indicates a moderate level of volatility, and a breakout above the SMA200 at $38.98 could signal a bullish trend. If the stock can maintain momentum and break through resistance levels, it may be poised for further growth, potentially targeting the upper end of its 52-week range range.

>

Fundamentally, Legend Biotechs market capitalization stands at approximately $5320.28 million, with a negative Return on Equity (ROE) of -20.14.14, reflecting the companys significant investment in research and development development. The absence of a trailing P/E ratio is not surprising, given the companys stage of development and lack of profitability. However, the forward P/E ratio of of 100.00 suggests that investors are pricing in significant growth potential. As the company progresses its pipeline and potentially brings its therapies to market, it may be able to improve its financial performance. A key catalyst for growth could growth could be the successful commercialization of cilftacabtagene autole autoleucel, which could significantly impact the companys revenue and, subsequently, its valuation.

Looking ahead, if Legend Biotech canLegend Biotech can continue to advance its clinical trials and forge strategic partnerships, the potential for growth is substantial. A forecast based on both technical and fundamental data suggests that if the company cans if the company can successfully navigate the regulatory landscape and bring its therapies to therapies to market, the stock could see significant upside. A potential target could be a price level above $50.00, driven by a combination of positive clinical trial results, successful commercialization, and an expanding market presence. However, this forecast is contingent on the companys ability companys ability to execute on its pipeline and navigate the inherent risks associated with the biotechnology sector.

Additional Sources for LEGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

LEGN Stock Overview

Market Cap in USD 6,229m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2020-06-05

LEGN Stock Ratings

Growth Rating -11.9
Fundamental -26.7
Dividend Rating 0.0
Rel. Strength -13.5
Analysts 4.45 of 5
Fair Price Momentum 29.99 USD
Fair Price DCF -

LEGN Dividends

Currently no dividends paid

LEGN Growth Ratios

Growth Correlation 3m 21.7%
Growth Correlation 12m -86.4%
Growth Correlation 5y 36.9%
CAGR 5y -2.17%
CAGR/Max DD 5y -0.03
Sharpe Ratio 12m -0.95
Alpha -31.03
Beta 0.648
Volatility 54.99%
Current Volume 1450.4k
Average Volume 20d 1972.3k
What is the price of LEGN shares?
As of July 01, 2025, the stock is trading at USD 35.49 with a total of 1,450,356 shares traded.
Over the past week, the price has changed by +4.84%, over one month by +21.04%, over three months by +4.60% and over the past year by -22.88%.
Is Legend Biotech a good stock to buy?
Probably not. Based on ValueRay´s Fundamental Analyses, Legend Biotech (NASDAQ:LEGN) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.66 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LEGN is around 29.99 USD . This means that LEGN is currently overvalued and has a potential downside of -15.5%.
Is LEGN a buy, sell or hold?
Legend Biotech has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LEGN.
  • Strong Buy: 11
  • Buy: 10
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for LEGN share price target?
According to our own proprietary Forecast Model, LEGN Legend Biotech will be worth about 33.9 in July 2026. The stock is currently trading at 35.49. This means that the stock has a potential downside of -4.59%.
Issuer Target Up/Down from current
Wallstreet Target Price 76.4 115.3%
Analysts Target Price 76.7 116.2%
ValueRay Target Price 33.9 -4.6%